PRI-101 / Priavoid - LARVOL DELTA

Disassembly of α-Synuclein Aggregates by the All-D-peptide PRI-101: Preclinical Efficacy in Vitro and in Vivo. (MDS Congress 2026) - No abstract available

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Establishment of an Agrobacterium-Mediated Genetic Transformation System for Prunus sibirica and Its Preliminary Application in PsWRKY17 Overexpression Under Low-Temperature Stress. (PubMed, Physiol Plant) - "The genetic transformation system utilized A. tumefaciens strain GV3101 carrying reporter vectors pRI101-GFP or pCAMBIA1301-GUS, with optimal parameters including a 3-day preculture, infection at OD600 = 0.6 for 20 min, and a 2-day coculture. Transformants were selected in a medium containing 20 mg L-1 kanamycin and 300 mg L-1 cefotaxime, achieving an average transformation efficiency of 11.27%...However, the regulatory mechanism of PsWRKY17 requires further investigation. In summary, an effective regeneration and genetic transformation system for P. sibirica was developed, providing a foundation for future research and biotechnological applications."

Journal • Gene Therapies • Infectious Disease

ALL-D-ENANTIOMERIC PEPTIDE WITH ANTI-PRIONIC MODE OF ACTION REVERSES Α-SYNUCLEIN PATHOLOGY IN A TRANSGENIC PARKINSON'S DISEASE MOUSE MODEL (THY1-ΑSYN, "LINE 61") (ADPD 2026) - "Here, we report the effects of an all-d-enantiomeric peptide, PRI-101, that binds α-syn monomers with high affinity, stabilizes their native state, prevents aggregation, and disassembles preformed fibrils in an anti-prionic mode of action (MoA). Male transgenic Line 61 mice overexpressing human wild-type α-syn under the Thy1 promoter were treated orally with the peptide, starting at 3 weeks of age, for 7 weeks (short-term) or 19 weeks (long-term)... These data identify a first-in-class all-d-enantiomeric peptide with an anti-prionic MoA that reverses α-syn pathology in vivo. The findings establish a novel, non-immunological, disease-modifying therapeutic approach for PD and related synucleinopathies, with ongoing analyses to further substantiate its disease-modifying efficacy."

Preclinical • CNS Disorders • Mood Disorders • Movement Disorders • Parkinson's Disease • NEFL • THY1

TITLE: DISASSEMBLY OF Α-SYNUCLEIN AGGREGATES BY THE ALL-D-PEPTIDE PRI-101: PRECLINICAL EFFICACY IN VITRO AND IN VIVO. (ADPD 2026) - "The all-D-peptide PRI-101 binds α-syn with high affinity, inhibits aggregation, and disassembles fibrils in vitro, in cells, and prolongs median survival in the TgM83+/− heterozygouzs murine PD model. PRI-101 thus represents a novel therapeutic class with a distinct MoA for the treatment of PD and related synucleinopathies."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

PRI-101 could become first disease-modifying Parkinson’s drug (Drug Target Review) - "The findings will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders 2026 in Copenhagen...In vitro experiments showed that the drug could disassemble preformed fibrils of α-synuclein and deactivate their ability to spread, with effects increasing over time and at higher concentrations. Ex vivo studies using post-mortem brain samples from patients with Parkinson’s disease, multiple system atrophy and Lewy body dementia also showed reduced levels of these aggregates....Further pharmacokinetic testing confirmed that PRI-101 can cross the blood-brain barrier and reach the brain in meaningful concentrations....Priavoid plans to continue advancing PRI-101 towards clinical development, with the aim of evaluating its safety and effectiveness in human patients."

Preclinical • Parkinson's Disease

Priavoid…announced it will present…preclinical proof-of-concept data for its candidate PRI-101 in alpha-synucleinopathy models like Parkinson’s disease (PD) at the upcoming AD/PD 2026 International Conference (GlobeNewswire) - "The preclinical proof-of-concept data for PRI-101, a candidate designed to target alpha-synuclein (α-syn) aggregates, will be shared as a poster presentation and include encouraging efficacy data in several in vitro and in vivo PD models."

Preclinical • Parkinson's Disease